Exosomal circRNAs in the plasma serve as novel biomarkers for IPF diagnosis and progression predictionWenhua Gan, Xin Yan, Fengjuan Wang et al.|Journal of Translational Medicine|2024Cited by 18
AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancerJung‐Yun Lee, Lingying Wu, Sathana Boonyapipat et al.|Gynecologic Oncology|2025Cited by 7